Cargando…
Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis
Immunoproteasome (IP) inhibition holds potential as a novel treatment option for various immune-mediated pathologies. The IP inhibitor ONX 0914 reduced T cell cytokine secretion and Th17 polarization and showed pre-clinical efficacy in a range of autoimmune disorders, transplant-allograft rejection,...
Autores principales: | Schmidt, Christian, Berger, Thilo, Groettrup, Marcus, Basler, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212513/ https://www.ncbi.nlm.nih.gov/pubmed/30416500 http://dx.doi.org/10.3389/fimmu.2018.02386 |
Ejemplares similares
-
Immunoproteasome Inhibition Reduces the T Helper 2 Response in Mouse Models of Allergic Airway Inflammation
por: Oliveri, Franziska, et al.
Publicado: (2022) -
On the Role of the Immunoproteasome in Protein Homeostasis
por: Basler, Michael, et al.
Publicado: (2021) -
Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis
por: Basler, Michael, et al.
Publicado: (2014) -
Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice
por: Mundt, Sarah, et al.
Publicado: (2016) -
Immunoproteasome inhibition attenuates experimental psoriasis
por: del Rio Oliva, Marta, et al.
Publicado: (2022)